Multi-analyte Blood Test Clinical Trial
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHelio Genomics
About this trial
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Eligibility criteria
Qualifiers
Age 18 years or older.
Males and Females.
Having cirrhosis or meeting the AASLD guidelines for HCC
surveillance.
Disqualifiers
Subjects that are unwilling or unable to sign the Informed Consent Form will be excluded.
Known cancer diagnosis of a cancer other than HCC within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.
Trial design
Treatments tested in this trial
- Multi-analyte Blood Test
Treatment groups
1,200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov